C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection

Summary

This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing antibody mediated injury. A maximum of 5 patients will be enrolled.

Timeline

Start

2016-10

Primary completion

2018-10-30

Completion

2018-10-30

Drugs

Indications